The future of personalised radiotherapy for head and neck cancer.

[1]  M. Baumann,et al.  Early FDG PET at 10 or 20 Gy under chemoradiotherapy is prognostic for locoregional control and overall survival in patients with head and neck cancer , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[2]  Steven Eschrich,et al.  Prediction of radiation sensitivity using a gene expression classifier. , 2005, Cancer research.

[3]  M. Hatt,et al.  18F-FDG PET Uptake Characterization Through Texture Analysis: Investigating the Complementary Nature of Heterogeneity and Functional Tumor Volume in a Multi–Cancer Site Patient Cohort , 2015, The Journal of Nuclear Medicine.

[4]  P. Remeijer,et al.  OC-0350: Geometric changes of parotid glands caused by pre- and posthydration during chemoradiotherapy , 2013 .

[5]  Xiangyu Yang,et al.  Quantifying Tumor Vascular Heterogeneity with Dynamic Contrast-Enhanced Magnetic Resonance Imaging: A Review , 2011, Journal of biomedicine & biotechnology.

[6]  D. Gabrilovich,et al.  Radiation-induced autophagy potentiates immunotherapy of cancer via up-regulation of mannose 6-phosphate receptor on tumor cells in mice , 2014, Cancer Immunology, Immunotherapy.

[7]  Crispin J. Miller,et al.  A 26-Gene Hypoxia Signature Predicts Benefit from Hypoxia-Modifying Therapy in Laryngeal Cancer but Not Bladder Cancer , 2013, Clinical Cancer Research.

[8]  Benjamin Haibe-Kains,et al.  Radiomic feature clusters and Prognostic Signatures specific for Lung and Head & Neck cancer , 2015, Scientific Reports.

[9]  Richard Stock,et al.  Meta-analysis of Genome Wide Association Studies Identifies Genetic Markers of Late Toxicity Following Radiotherapy for Prostate Cancer , 2016, EBioMedicine.

[10]  R. Weber,et al.  A Phase III Trial to Test Accelerated Versus Standard Fractionation in Combination with Concurrent Cisplatin for Head and Neck Carcinomas (RTOG 0129): Report of Efficacy and Toxicity , 2010 .

[11]  Frank J P Hoebers,et al.  Gene expression profiling to predict outcome after chemoradiation in head and neck cancer. , 2007, International journal of radiation oncology, biology, physics.

[12]  Jens Overgaard,et al.  Impact of HPV-associated p16-expression on radiotherapy outcome in advanced oropharynx and non-oropharynx cancer. , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[13]  C. Chung,et al.  ECOG 1308: A phase II trial of induction chemotherapy followed by cetuximab with low dose versus standard dose IMRT in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx (OP). , 2012 .

[14]  P. Lambin,et al.  TH-302 in Combination with Radiotherapy Enhances the Therapeutic Outcome and Is Associated with Pretreatment [18F]HX4 Hypoxia PET Imaging , 2015, Clinical Cancer Research.

[15]  Fréderic Duprez,et al.  Maximum tolerated dose in a phase I trial on adaptive dose painting by numbers for head and neck cancer. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[16]  S. Demaria,et al.  Systemic effects of local radiotherapy. , 2009, The Lancet. Oncology.

[17]  M. Sydes,et al.  Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study. , 2012, The Lancet. Oncology.

[18]  B. Ross,et al.  Mathematical Modeling of PDGF-Driven Glioblastoma Reveals Optimized Radiation Dosing Schedules , 2014, Cell.

[19]  Jens Overgaard,et al.  Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  K. Iwamoto,et al.  Maximizing tumor immunity with fractionated radiation. , 2012, International journal of radiation oncology, biology, physics.

[21]  L. Wilson,et al.  Supply and Demand for Radiation Oncology in the United States: Updated Projections for 2015 to 2025. , 2016, International journal of radiation oncology, biology, physics.

[22]  David Boulware,et al.  A gene expression model of intrinsic tumor radiosensitivity: prediction of response and prognosis after chemoradiation. , 2009, International journal of radiation oncology, biology, physics.

[23]  D. Knol,et al.  Predictive value of diffusion-weighted imaging without and with including contrast-enhanced magnetic resonance imaging in image analysis of head and neck squamous cell carcinoma. , 2015, European journal of radiology.

[24]  P. Lambin,et al.  A phase 1 ‘window-of-opportunity’ trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients , 2016, BMC Cancer.

[25]  W. Weichert,et al.  Comparative analysis of transcriptomics based hypoxia signatures in head- and neck squamous cell carcinoma. , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[26]  Petra Seibold,et al.  Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients. , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[27]  D. Sher,et al.  Stereotactic body radiotherapy and treatment at a high volume facility is associated with improved survival in patients with inoperable stage I non-small cell lung cancer. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[28]  Sue S Yom,et al.  Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Shao Hui Huang,et al.  External validation of a prognostic CT-based radiomic signature in oropharyngeal squamous cell carcinoma , 2015, Acta oncologica.

[30]  P. Glazer,et al.  Molecular and Cellular Pharmacology of the Hypoxia-Activated Prodrug TH-302 , 2011, Molecular Cancer Therapeutics.

[31]  Baojun Li,et al.  Difference Between HPV-Positive and HPV-Negative Non-Oropharyngeal Head and Neck Cancer: Texture Analysis Features on CT , 2016, Journal of computer assisted tomography.

[32]  Johan Wennerberg,et al.  2-Deoxy-2-[18F] fluoro-D-glucose uptake and correlation to intratumoral heterogeneity. , 2007, Anticancer research.

[33]  N. Kawashima,et al.  Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti–CTLA-4 Antibody , 2009, Clinical Cancer Research.

[34]  R. Arceci.  Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing , 2012 .

[35]  U. Lendahl,et al.  Generating specificity and diversity in the transcriptional response to hypoxia , 2009, Nature Reviews Genetics.

[36]  M. M. Qureshi,et al.  Using Texture Analysis to Determine Human Papillomavirus Status of Oropharyngeal Squamous Cell Carcinomas on CT , 2015, American Journal of Neuroradiology.

[37]  Patrick Granton,et al.  Radiomics: extracting more information from medical images using advanced feature analysis. , 2012, European journal of cancer.

[38]  P. Lambin,et al.  Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach , 2014, Nature Communications.

[39]  Jacob G. Scott,et al.  A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study. , 2017, The Lancet. Oncology.

[40]  A. Kishan,et al.  Anatomic and dosimetric changes in patients with head and neck cancer treated with an integrated MRI-tri-60Co teletherapy device. , 2016, The British journal of radiology.

[41]  Johannes A Langendijk,et al.  Identifying patients who may benefit from adaptive radiotherapy: Does the literature on anatomic and dosimetric changes in head and neck organs at risk during radiotherapy provide information to help? , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[42]  R. Weichselbaum,et al.  Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. , 2014, The Journal of clinical investigation.

[43]  B. S. Sørensen,et al.  Development of a hypoxia gene expression classifier with predictive impact for hypoxic modification of radiotherapy in head and neck cancer. , 2011, Cancer research.

[44]  V. Quaranta,et al.  Integrative mathematical oncology , 2008, Nature Reviews Cancer.

[45]  Gypsyamber D'Souza,et al.  HPV-associated head and neck cancer: a virus-related cancer epidemic. , 2010, The Lancet. Oncology.

[46]  Drew A. Torigian,et al.  Evolving role of molecular imaging with PET in detecting and characterizing heterogeneity of cancer tissue at the primary and metastatic sites, a plausible explanation for failed attempts to cure malignant disorders , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[47]  M. Urken,et al.  Use of Cone Beam CT to Assess Midtreatment Nodal Response to Chemoradiation Therapy in Oropharyngeal Squamous Cell Carcinomas: Implications for Adaptive Radiation Therapy , 2015 .

[48]  P. Lambin,et al.  Predicting outcomes in radiation oncology—multifactorial decision support systems , 2013, Nature Reviews Clinical Oncology.

[49]  M. J. van de Vijver,et al.  Integration of a Radiosensitivity Molecular Signature Into the Assessment of Local Recurrence Risk in Breast Cancer. , 2015, International journal of radiation oncology, biology, physics.

[50]  H. Fujii,et al.  Radiotherapy-Induced Anti-Tumor Immunity Contributes to the Therapeutic Efficacy of Irradiation and Can Be Augmented by CTLA-4 Blockade in a Mouse Model , 2014, PloS one.

[51]  Paul Kinahan,et al.  Radiomics: Images Are More than Pictures, They Are Data , 2015, Radiology.

[52]  J. Petersen,et al.  Imaging hypoxia to improve radiotherapy outcome , 2012, Nature Reviews Clinical Oncology.

[53]  Anne Bol,et al.  Hypoxia-guided adaptive radiation dose escalation in head and neck carcinoma: A planning study , 2015, Acta oncologica.

[54]  Kujtim Latifi,et al.  A proliferation saturation index to predict radiation response and personalize radiotherapy fractionation , 2015, Radiation oncology.

[55]  B. Hann,et al.  TGFβ1 Inhibition Increases the Radiosensitivity of Breast Cancer Cells In Vitro and Promotes Tumor Control by Radiation In Vivo , 2011, Clinical Cancer Research.

[56]  R. Weichselbaum,et al.  Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. , 2009, Blood.

[57]  V. Sondak,et al.  12-Chemokine Gene Signature Identifies Lymph Node-like Structures in Melanoma: Potential for Patient Selection for Immunotherapy? , 2012, Scientific Reports.

[58]  J. Fowler.  Linear quadratics is alive and well: in regard to Park et al. (Int J Radiat Oncol Biol Phys 2008;70:847-852). , 2008, International journal of radiation oncology, biology, physics.

[59]  J. Deasy,et al.  Estimate of the impact of FDG-avidity on the dose required for head and neck radiotherapy local control , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[60]  Philip Hahnfeldt,et al.  Simple ODE models of tumor growth and anti-angiogenic or radiation treatment , 2001 .

[61]  L. Peters,et al.  Effect of host immune capability on radiocurability and subsequent transplantability of a murine fibrosarcoma. , 1979, Journal of the National Cancer Institute.

[62]  Sunita Ghosh,et al.  Outcomes in stage I non-small cell lung cancer following the introduction of stereotactic body radiotherapy in Alberta - A population-based study. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[63]  Daniela Thorwarth,et al.  Implementation of hypoxia imaging into treatment planning and delivery. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.